CETP inhibitors

Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C560S132000, C564S336000, C564S337000, C514S476000

Reexamination Certificate

active

07737295

ABSTRACT:
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

REFERENCES:
patent: 2002/0035136 (2002-03-01), Liu et al.
patent: 2005/0059810 (2005-03-01), Maeda et al.
patent: WO03/064376 (2003-08-01), None
patent: WO2004/020393 (2004-03-01), None
patent: WO2004/092136 (2004-10-01), None
Lin N-H et al. “Siynthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor”; Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB; vol. 14, No. 20, Oct. 18, 2004 pp. 5057-5062 XP004565431; Compounds 20, 21.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

CETP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CETP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CETP inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4229880

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.